Rapid, complete and sustained tumour response to the TRK inhibitor larotrectinib in an infant with recurrent, chemotherapy-refractory infantile fibrosarcoma carrying the characteristic ETV6-NTRK3 gene fusion

BACKGROUND: The ETV6-NTRK3 gene fusion is present in the majority of cases of infantile fibrosarcoma (IFS) and acts as a potent oncogenic driver. We report the very rapid, complete, and sustained response of an advanced, chemotherapy-refractory, recurrent IFS to targeted treatment with the oral trop...

詳細記述

保存先:
書誌詳細
出版年:Ann Oncol
主要な著者: Bielack, S S, Cox, M C, Nathrath, M, Apel, K, Blattmann, C, Holl, T, Jenewein, R, Klenk, U, Klothaki, P, Müller-Abt, P, Ortega-Lawerenz, S, Reynolds, M, Scheer, M, Simon-Klingenstein, K, Stegmaier, S, Tupper, R, Vokuhl, C, von Kalle, T
フォーマット: Artigo
言語:Inglês
出版事項: Oxford University Press 2019
主題:
Original Articles
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC6859811/
https://ncbi.nlm.nih.gov/pubmed/31738425
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdz382
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料